George Morstyn
Director/Board Member bij ACTINOGEN MEDICAL LIMITED
Vermogen: 98 088 $ op 31-03-2024
Profiel
George Morstyn is currently the Chief Executive Officer at G & R Morstyn Pty Ltd.
He is also an Independent Director at Cancer Therapeutics CRC Pty Ltd., a Non-Executive Director at Actinogen Medical Ltd., an Investment Committee Member at GBS Venture Partners Pty Ltd., and a Member at the Australian Institute of Co. Directors.
In the past, Dr. Morstyn has served as the Deputy Chairman-Joint Venture Board at Victorian Comprehensive Cancer Centre Pty Ltd., a Director at Proacta, Inc., an Independent Non-Executive Director at ChemGenex Pharmaceuticals Pty Ltd., a Director at Bionomics Ltd., a Non-Executive Director at ChemGenex Pharmaceuticals, Inc., a Director-Supervisory Board at Amsterdam Molecular Therapeutics (AMT) Holding NV, an Outside Director at SymBio Pharmaceuticals Ltd., a Director at Glykoz Pharma Discovery Pty Ltd., and a Director at Cancer Trials Australia.
He has also worked as the Chief Medical Officer & Senior VP-Development at Amgen, Inc. from 1991 to 2002 and as the Head-Clinical Program at Ludwig Institute for Cancer Research Ltd.
from 1983 to 1991.
Dr. Morstyn completed his undergraduate degree at Monash University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 30-06-2023 | 4 697 716 ( 0.20% ) | 98 088 $ | 31-03-2024 |
Actieve functies van George Morstyn
| Bedrijven | Functie | Begin |
|---|---|---|
| ACTINOGEN MEDICAL LIMITED | Director/Board Member | 01-12-2017 |
GBS Venture Partners Pty Ltd.
 GBS Venture Partners Pty Ltd. Investment ManagersFinance GBS Venture Partners Pty Ltd (GBS Venture Partners) is a venture capital firm founded in 1996 by Helen Brigitte Smith and Geoff E.D Brooke. The firm is headquartered in Melbourne. | Investment Committee Member | - |
| G & R Morstyn Pty Ltd. | Chief Executive Officer | 01-04-2006 |
Cancer Therapeutics CRC Pty Ltd.
 Cancer Therapeutics CRC Pty Ltd. BiotechnologyHealth Technology Cancer Therapeutics CRC Pty Ltd. engages in research and development novel oncology drug and clinical diseases. It focuses in recombinant protein production, structural biology, DMPK, and translational cancer biology. The company was founded in 2007 and is headquartered in Melbourne, Australia. | Director/Board Member | - |
Australian Institute of Co. Directors
 Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Australian Institute of Co. Directors is a non-profit organization that provides leadership on director issues. It offers governance education, director development, and advocacy. The organization was founded in January 1, 1990 and is headquartered in Sydney, Australia. | Corporate Officer/Principal | - |
Eerdere bekende functies van George Morstyn
| Bedrijven | Functie | Einde |
|---|---|---|
ChemGenex Pharmaceuticals Pty Ltd.
 ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | Director/Board Member | 07-06-2011 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Corporate Officer/Principal | 20-09-2010 |
| BIONOMICS LIMITED | Director/Board Member | 01-01-2006 |
| AMGEN INC. | Chief Tech/Sci/R&D Officer | 01-01-2002 |
| ░░░░░░ ░░░░░░░░░ ░░░ ░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van George Morstyn
| Monash University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| AMGEN INC. | Health Technology |
| BIONOMICS LIMITED | Health Technology |
| ACTINOGEN MEDICAL LIMITED | Health Technology |
| SYMBIO PHARMACEUTICALS LIMITED | Health Technology |
| Bedrijven in privébezit | 12 |
|---|---|
Proacta, Inc.
 Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Health Technology |
Cancer Therapeutics CRC Pty Ltd.
Cancer Therapeutics CRC Pty Ltd. BiotechnologyHealth Technology Cancer Therapeutics CRC Pty Ltd. engages in research and development novel oncology drug and clinical diseases. It focuses in recombinant protein production, structural biology, DMPK, and translational cancer biology. The company was founded in 2007 and is headquartered in Melbourne, Australia. | Health Technology |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | Health Technology |
ChemGenex Pharmaceuticals, Inc.
 ChemGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals, Inc. manufactures and develops pharmaceuticals. It develops novel protein, antibody, & small molecule therapeutics in the areas of oncology, obesity, diabetes, and central nervous system disorders. The company is a subsidiary of Chemgenex Pharmaceuticals Ltd. It was founded in 2004 and is headquartered in Menlo Park, CA. | Health Technology |
GBS Venture Partners Pty Ltd.
GBS Venture Partners Pty Ltd. Investment ManagersFinance GBS Venture Partners Pty Ltd (GBS Venture Partners) is a venture capital firm founded in 1996 by Helen Brigitte Smith and Geoff E.D Brooke. The firm is headquartered in Melbourne. | Finance |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Commercial Services |
Australian Institute of Co. Directors
Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Australian Institute of Co. Directors is a non-profit organization that provides leadership on director issues. It offers governance education, director development, and advocacy. The organization was founded in January 1, 1990 and is headquartered in Sydney, Australia. | Commercial Services |
Ludwig Institute for Cancer Research Ltd.
 Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | Health Services |
Glykoz Pharma Discovery Pty Ltd.
 Glykoz Pharma Discovery Pty Ltd. Pharmaceuticals: MajorHealth Technology Glykoz Pharma Discovery Pty Ltd. develops carbohydrate based drugs. It also develops drug candidates for licensing to international biotechnology and pharmaceutical companies. The company was founded by Andrew Loch, Ross Coppel, Karyn Joyner, Mark von Itzstein and Richard J. McElhinney on 5 December, 2006 and is headquartered in Nerang, Australia. | Health Technology |
| Cancer Trials Australia | |
Victorian Comprehensive Cancer Centre Pty Ltd.
 Victorian Comprehensive Cancer Centre Pty Ltd. BiotechnologyHealth Technology Victorian Comprehensive Cancer Centre Pty Ltd. operates as a cancer research, treatment and education centre. The company was founded in 2009 and is headquartered in Melbourne, Australia. | Health Technology |
| G & R Morstyn Pty Ltd. |
